Aikido Pharma has made an investment in Convergent Therapeutics, a company developing a radiopharmaceutical for treating prostate cancer. Aikido made the investment in the form of a $2 million convertible promissory note purchase agreement.
Convergent is conducting human clinical trials using its peptide receptor radionuclide therapy (PRRT) technology, which targets the prostate-specific membrane antigen (PSMA) present on prostate cancer cells. A key component of PRRT is Convergent's proprietary drug, CONV 01-α, a monoclonal antibody conjugated with actinium-225, a radioactive alpha-particle emitter.
Convergent has two sets of human clinical trials underway that use CONV 01-α as a single-agent treatment for prostate cancer. The company has also developed a dual therapy by adding a second molecule that binds to PSMA and also has a radioactive isotope. Trials of this agent are expected to begin in February 2021.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
